Abstract
BackgroundA public-private (51/49 %) partnership was initiated in 2007 in France to improve the attractiveness of French sites in industry-sponsored international clinical trials. This initiative developed and implemented a combination of structuring actions and support actions. Here we report the assessment of the impact after 6 years on participation of French study sites in industry-sponsored clinical trials.MethodsWe performed a prospective before-after study of clinical research activities in French public hospitals to assess the impact of actions developed and implemented by CeNGEPS. The programme involved a combination of structuring actions (establishment of sites of excellence, national networks and dedicated clinical research assistants (CRAs)), support actions (tools, templates and training) and competitive budget allocation for sites or networks based on performance. The impact was assessed using the following performance criteria: 1) reduction of the delay to contract signature to ≤ 60 days for 80 % of the trial sites; 2) inclusion of ≥80 % of the planned number of patients by at least 80 % of trial sites; 3) closure of <15 % of trials sites without patients enrolled.ResultsIn 2013, the median delay to contract signature was: 55 days, compared with 76 days in 2008 (27.6 % reduction), 50.5 % of all sites and 58 % of sites with a dedicated CRA included ≥80 % of the planned number of patients compared with 44.8 % in 2008 (12.7 % increase) and 21.3 % of all sites and 9 % of sites with a dedicated CRA closed with no patients included, compared with 26.4 % in 2008 (19.3 and 65.9 %, respectively).ConclusionsThese results provide evidence that it is possible to improve a country’s attractiveness for industry-sponsored clinical research. The two main actions, i.e. establishing sites of excellence throughout the country with well-trained, dedicated staff and establishing a national network of clinical investigators, could be adapted to other countries in Western Europe to improve Europe’s attractiveness to industry-funded trials.
Highlights
A public-private (51/49 %) partnership was initiated in 2007 in France to improve the attractiveness of French sites in industry-sponsored international clinical trials
Description of the CeNGEPS initiative Using the British model of the Pharmaceutical Industry Competiveness Task Force (PICTF) created by Prime Minister Tony Blair, France set up a Strategic Advisory Committee for the Healthcare Industry [9, 10]
This committee was composed of the highest political authorities and representatives of the healthcare industries. Their aim was to develop recommendations for improving and maintaining the attractiveness of France for industry-sponsored international clinical trials, in the light of the major economic and political issues at stake; 250 000 to 300 000 jobs in France and a profit of over 7 billion euros [11]. This committee recommended the establishment of CeNGEPS to be at the centre of interactions between the different actors in industry-sponsored clinical trials in France: the healthcare organisations; the investigators; the industrial sponsors; and the patients and healthy volunteers
Summary
Description of the CeNGEPS initiative Using the British model of the Pharmaceutical Industry Competiveness Task Force (PICTF) created by Prime Minister Tony Blair, France set up a Strategic Advisory Committee for the Healthcare Industry (in French: ‘Conseil Stratégique des Industries de Santé’ – CSIS) [9, 10]. This committee was composed of the highest political authorities and representatives of the healthcare industries. All proposals are assessed by two rapporteurs, one academic and one industrial
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
